Feed Category: Women's Health Index

Revenue: No product sales recorded for Q1 FY2025 due to the sale of Vyleesi rights; previous year’s Q1 net product revenue was $2.1 million. Operating…

OvaSuite Revenue: $2.3 million in Q3 2024, a 2% increase from $2.2 million in Q3 2023. OvaSuite Test Volume: Increased 4% year-over-year for Q3 2024….

OvaSuite Revenue: $2.3 million in Q3 2024, a 2% increase from $2.2 million in Q3 2023. OvaSuite Test Volume: Increased 4% year-over-year for Q3 2024….

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.60. This…

Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation…

EAST PRINCETON, N.J. (AP) — EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Thursday reported a loss of $10.7 million in its third…

While “the trend is your friend” when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success….

– Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. – Grant will…

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — TherapeuticsMD Inc. (TXMD) on Tuesday reported a loss of $609,000 in its third quarter. The…

BOCA RATON, Fla., November 12, 2024–(BUSINESS WIRE)–TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial…

Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares…